

Wytske J Fokkens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9504286/publications.pdf>

Version: 2024-02-01

141
papers

11,805
citations

53794

45
h-index

28297

105
g-index

149
all docs

149
docs citations

149
times ranked

8629
citing authors

#	ARTICLE	IF	CITATIONS
1	Mepolizumab for chronic rhinosinusitis with nasal polyps (<sc>SYNAPSE</sc>): Inâ€depth sinus surgery analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2023, 78, 812-821.	5.7	14
2	Realâ€life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 670-674.	5.7	46
3	Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 337-346.	10.7	40
4	The prevalence of nonâ€allergic rhinitis phenotypes in the general population: A crossâ€sectional study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2163-2174.	5.7	17
5	Allergen immunotherapy in MASKâ€air users in realâ€life: Results of a Bayesian mixedâ€effects model. Clinical and Translational Allergy, 2022, 12, e12128.	3.2	9
6	Behavioural patterns in allergic rhinitis medication in Europe: A study using MASKâ€air^{Â®} realâ€world data. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2699-2711.	5.7	17
7	Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps. Annals of Allergy, Asthma and Immunology, 2022, 129, 160-168.	1.0	15
8	Combined medical and surgical therapy for chronic rhinosinusitis with nasal polyposis â€“ Authors' reply. Lancet Respiratory Medicine,the, 2022, 10, e39.	10.7	0
9	Comparison of rhinitis treatments using <sc>MASK</sc>â€airÂ® data and considering the minimal important difference. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3002-3014.	5.7	8
10	White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA. Frontiers in Allergy, 2022, 3, .	2.8	15
11	Migration and allergic diseases: Findings from a populationâ€based study in adults in Amsterdam, the Netherlands. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3667-3670.	5.7	0
12	COVIDâ€19 pandemic: Practical considerations on the organization of an allergy clinicâ€”An EAACI/ARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 648-676.	5.7	79
13	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	5.7	46
14	ARIAâ€EAACI statement on asthma and COVIDâ€19 (June 2, 2020). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 689-697.	5.7	57
15	Role of Biologics in Chronic Rhinosinusitis With Nasal Polyposis: State of the Art Review. Otolaryngology - Head and Neck Surgery, 2021, 164, 57-66.	1.9	21
16	Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVIDâ€19. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 735-750.	5.7	83
17	Management of patients with chronic rhinosinusitis during the COVIDâ€19 pandemicâ€”An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 677-688.	5.7	33
18	International consensus statement on allergy and rhinology: rhinosinusitis 2021. International Forum of Allergy and Rhinology, 2021, 11, 213-739.	2.8	398

#	ARTICLE	IF	CITATIONS
19	Steroid-resistant human inflammatory ILC2s are marked by CD45RO and elevated in type 2 respiratory diseases. <i>Science Immunology</i> , 2021, 6, .	11.9	65
20	Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. <i>Immunity</i> , 2021, 54, 291-307.e7.	14.3	134
21	Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2337-2353.	5.7	78
22	Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 575-585.	3.1	16
23	Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA- ² LEN consensus. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2354-2366.	5.7	31
24	Highlights in the advances of chronic rhinosinusitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3349-3358.	5.7	27
25	Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1640-1660.	5.7	72
26	Complete Remission of Severe Eosinophilic Otitis Media With Dupilumab: A Case Report. <i>Laryngoscope</i> , 2021, 131, 2649-2651.	2.0	8
27	A multicenter real-life study on the multiple reasons for uncontrolled allergic rhinitis. <i>International Forum of Allergy and Rhinology</i> , 2021, 11, 1452-1460.	2.8	9
28	Therapeutic Options for Chronic Rhinosinusitis in N-ERD Patients. <i>Frontiers in Allergy</i> , 2021, 2, 734000.	2.8	5
29	Legends of allergy and immunology: Niels Mygind. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3839-3840.	5.7	0
30	The extent of endoscopic sinus surgery in patients with severe chronic rhinosinusitis with nasal polyps (AirGOs Operative). <i>Rhinology</i> , 2021, 4, 154-160.	0.3	5
31	Mometasone furoate and fluticasone furoate are equally effective in restoring nasal epithelial barrier dysfunction in allergic rhinitis. <i>World Allergy Organization Journal</i> , 2021, 14, 100585.	3.5	8
32	Management of anaphylaxis due to COVID-19 vaccines in the elderly. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2952-2964.	5.7	16
33	Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK- ^{air} . <i>Clinical and Translational Allergy</i> , 2021, 11, e12062.	3.2	31
34	Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1141-1153.	10.7	263
35	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 70-80.e3.	2.9	272
36	Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. <i>Clinical and Translational Allergy</i> , 2020, 10, 1.	3.2	110

#	ARTICLE	IF	CITATIONS
37	Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 3039-3068.	5.7	127
38	Real-life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2867-2878.	5.7	45
39	A compendium answering 150 questions on COVID-19 and SARS-CoV-2. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2503-2541.	5.7	95
40	Direct and indirect costs of allergic and non-allergic rhinitis in the Netherlands. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2993-2996.	5.7	15
41	Clinical Research Needs for the Management of Chronic Rhinosinusitis with Nasal Polyps in the New Era of Biologics: A National Institute of Allergy and Infectious Diseases Workshop. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1532-1549.e1.	3.8	38
42	Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air App. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1672-1688.	5.7	32
43	Prevalence and impact of nasal hyperreactivity in chronic rhinosinusitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1768-1771.	5.7	14
44	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 350.	2.9	0
45	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. <i>Allergo Journal International</i> , 2019, 28, 255-276.	2.0	22
46	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases Meeting Report (Part 1). <i>Journal of Thoracic Disease</i> , 2019, 11, 3633-3642.	1.4	11
47	The prevalence of asthma in adult population of southwestern Iran and its association with chronic rhinosinusitis: a GA2LEN study. <i>Clinical and Translational Allergy</i> , 2019, 9, 43.	3.2	10
48	Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. <i>Lancet, The</i> , 2019, 394, 1638-1650.	13.7	812
49	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. <i>Clinical and Translational Allergy</i> , 2019, 9, 44.	3.2	87
50	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases Meeting Report (Part 2). <i>Journal of Thoracic Disease</i> , 2019, 11, 4072-4084.	1.4	15
51	Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2293-2311.	5.7	76
52	EUFOREA consensus on biologics for CRSwNP with or without asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2312-2319.	5.7	239
53	IL-1 β , IL-23, and TGF- β 2 drive plasticity of human ILC2s towards IL-17-producing ILCs in nasal inflammation. <i>Nature Communications</i> , 2019, 10, 2162.	12.8	95
54	Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 135-143.e6.	2.9	101

#	ARTICLE	IF	CITATIONS
55	Medical algorithms: Management of chronic rhinosinusitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1415-1416.	5.7	11
56	2019 ARIA Care pathways for allergen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2087-2102.	5.7	140
57	Novel roles for nasal epithelium in the pathogenesis of chronic rhinosinusitis with nasal polyps. <i>Rhinology</i> , 2019, 57, 0-0.	1.3	4
58	Prevalence of chronic rhinosinusitis in the general population based on sinus radiology and symptomatology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1207-1214.	2.9	152
59	Oral and intranasal aspirin desensitisation for non-steroidal anti-inflammatory drug (NSAID)-exacerbated respiratory disease. <i>The Cochrane Library</i> , 2019, , .	2.8	1
60	Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2511-2523.	3.8	44
61	<scp>ARIA</scp> pharmacy 2018 â€œAllergic rhinitis care pathways for community pharmacyâ€. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1219-1236.	5.7	52
62	Adherence to treatment in allergic rhinitis using mobile technology. The <scp>MASK</scp> Study. <i>Clinical and Experimental Allergy</i> , 2019, 49, 442-460.	2.9	73
63	New delivery forms of nasal corticosteroids. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 87-88.	2.9	7
64	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 864-879.	2.9	103
65	Mobile health tools for the management of chronic respiratory diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1292-1306.	5.7	66
66	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. <i>Allergologie Select</i> , 2019, 3, 22-50.	3.1	70
67	Intranasal corticosteroids for non-allergic rhinitis. <i>The Cochrane Library</i> , 2019, 2019, .	2.8	9
68	Precision Medicine in Chronic Rhinosinusitis with Nasal Polyps. <i>Current Allergy and Asthma Reports</i> , 2018, 18, 25.	5.3	71
69	Endotyping of non-allergic, allergic and mixed rhinitis patients using a broad panel of biomarkers in nasal secretions. <i>PLoS ONE</i> , 2018, 13, e0200366.	2.5	14
70	Rhinology Future Debates 2017 by <scp>EUFOREA</scp>: Novel treatments and surgical solutions in rhinology. <i>Clinical Otolaryngology</i> , 2018, 43, 1429-1438.	1.2	3
71	Dietary patterns and respiratory health in adults from nine European countriesâ€”Evidence from the CA²LEN study. <i>Clinical and Experimental Allergy</i> , 2018, 48, 1474-1482.	2.9	14
72	Acute and chronic rhinosinusitis and allergic rhinitis in relation to comorbidity, ethnicity and environment. <i>PLoS ONE</i> , 2018, 13, e0192330.	2.5	45

#	ARTICLE	IF	CITATIONS
73	Eye for an eye: near-fatal outcome of fungal infection in a young, diabetic girl. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-223059.	0.5	1
74	Endoscopic sinus surgery in adult patients with chronic rhinosinusitis with nasal polyps (PolypESS): study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 39.	1.6	14
75	The International Classification of the radiological Complexity (ICC) of frontal recess and frontal sinus. <i>International Forum of Allergy and Rhinology</i> , 2017, 7, 332-337.	2.8	11
76	Safety and efficacy of a bioabsorbable fluticasone propionate-eluting sinus dressing in postoperative management of endoscopic sinus surgery: a randomized clinical trial. <i>International Forum of Allergy and Rhinology</i> , 2017, 7, 813-820.	2.8	33
77	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 950-958.	2.9	1,199
78	Tranexamic acid for the reduction of bleeding during functional endoscopic sinus surgery. <i>The Cochrane Library</i> , 2017, .	2.8	3
79	Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1024-1031.e14.	2.9	376
80	Activity of Bacteriophages in Removing Biofilms of <i>Pseudomonas aeruginosa</i> Isolates from Chronic Rhinosinusitis Patients. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 418.	3.9	132
81	Endotype-driven treatment in chronic upper airway diseases. <i>Clinical and Translational Allergy</i> , 2017, 7, 22.	3.2	117
82	European Summit on the Prevention and Self-Management of Chronic Respiratory Diseases: report of the European Union Parliament Summit (29 March 2017). <i>Clinical and Translational Allergy</i> , 2017, 7, 49.	3.2	48
83	Dendritic Cell Subsets in Oral Mucosa of Allergic and Healthy Subjects. <i>PLoS ONE</i> , 2016, 11, e0154409.	2.5	11
84	Challenges in the Management of Inverted Papilloma: A Review of 72 Revision Cases. <i>Laryngoscope</i> , 2016, 126, 322-328.	2.0	31
85	Shape of the Osseous External Auditory Canal and Its Relationship to Troublesome Cavities. <i>Laryngoscope</i> , 2016, 126, 693-698.	2.0	2
86	Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study. <i>International Forum of Allergy and Rhinology</i> , 2016, 6, 557-567.	2.8	55
87	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 367-374.e2.	2.9	128
88	IL-1 β , IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. <i>Nature Immunology</i> , 2016, 17, 636-645.	14.5	397
89	Capsaicin for Rhinitis. <i>Current Allergy and Asthma Reports</i> , 2016, 16, 60.	5.3	31
90	International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. <i>International Forum of Allergy and Rhinology</i> , 2016, 6, S22-209.	2.8	443

#	ARTICLE	IF	CITATIONS
91	è;#æ•â'Æé¼4»çš'â- â¼½é™...â...±è-†â£°æ~Ž : é¼4»çª ç,Ž. International Forum of Allergy and Rhinology, 2016, 6, S228		339
92	Recent pharmacological developments in the treatment of perennial and persistent allergic rhinitis. Expert Opinion on Pharmacotherapy, 2016, 17, 657-669.	1.8	14
93	Novel, Alternative, and Controversial Therapies of Rhinitis. Immunology and Allergy Clinics of North America, 2016, 36, 401-423.	1.9	7
94	Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. Journal of Allergy and Clinical Immunology, 2016, 137, 1449-1456.e4.	2.9	833
95	Specific Induction of TSLP by the Viral RNA Analogue Poly(I:C) in Primary Epithelial Cells Derived from Nasal Polyyps. PLoS ONE, 2016, 11, e0152808.	2.5	22
96	Phenotyping, endotyping and clinical decision-making. Rhinology, 2016, 54, 97-98.	1.3	6
97	Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study. Rhinology, 2016, 54, 117-128.	1.3	38
98	Endoscopic sinus surgery and musculoskeletal symptoms. Rhinology, 2016, 54, 105-110.	1.3	17
99	The â€ˆGAÂ²LEN Sinusitis Cohortâ€™™: an introduction. Clinical and Translational Allergy, 2015, 5, O1.	3.2	4
100	Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype delta F508/S1215N. Clinical and Translational Allergy, 2015, 5, P2.	3.2	0
101	Breaking nasal epithelial cell tolerance lipopolysaccharide exposure by CD16Â-mediated coâ€™stimulation with human serum immunoglobulin G. Clinical and Translational Allergy, 2015, 5, P4.	3.2	1
102	Acute and chronic rhinosinusitis and allergic rhinitis in relation to environment, comorbidity and ethnicity. Clinical and Translational Allergy, 2015, 5, P26.	3.2	1
103	Patient reported outcome measurements in chronic rhinosinusitis; assessing the correlation between RSOMâ€™31 and VAS.. Clinical and Translational Allergy, 2015, 5, P28.	3.2	0
104	A new allergic rhinitis therapy (MP29â€™02*) provides effective and rapid symptom relief for patients who suffer most from the bothersome symptoms of nasal congestion or ocular itch. Clinical and Translational Allergy, 2015, 5, P33.	3.2	1
105	A new allergic rhinitis therapy (MP29â€™02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies. Clinical and Translational Allergy, 2015, 5, P34.	3.2	0
106	MP29â€™02*â€™™s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis. Clinical and Translational Allergy, 2015, 5, P36.	3.2	1
107	A new intranasal therapy (MP29â€™02*) is more effective than current firstline therapy regardless of season, symptom or severity.. Clinical and Translational Allergy, 2015, 5, P38.	3.2	1
108	Identification of gaps in the current allergic rhinitis guidelines and how these can be filled. Clinical and Translational Allergy, 2015, 5, P39.	3.2	0

#	ARTICLE	IF	CITATIONS
109	A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress. <i>Clinical and Translational Allergy</i> , 2015, 5, 36.	3.2	23
110	Rhinosinusitis in morbidity registrations in Dutch General Practice: a retro-spective case-control study. <i>BMC Family Practice</i> , 2015, 16, 120.	2.9	9
111	EGR-1 and DUSP-1 are important negative regulators of pro-allergic responses in airway epithelium. <i>Molecular Immunology</i> , 2015, 65, 43-50.	2.2	20
112	Synergy between TLR-2 and TLR-3 signaling in primary human nasal epithelial cells. <i>Immunobiology</i> , 2015, 220, 445-451.	1.9	13
113	Guidelines in otorhinolaryngology: a critical view. <i>Brazilian Journal of Otorhinolaryngology</i> , 2015, 81, 345-346.	1.0	0
114	Avoid prescribing antibiotics in acute rhinosinusitis. <i>BMJ, The</i> , 2014, 349, g5703-g5703.	6.0	17
115	ICON: chronic rhinosinusitis. <i>World Allergy Organization Journal</i> , 2014, 7, 25.	3.5	157
116	Evidence-based Surgery for Chronic Rhinosinusitis with and without Nasal Polyps. <i>Current Allergy and Asthma Reports</i> , 2014, 14, 427.	5.3	51
117	Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1608-1614.e6.	2.9	177
118	High Degree of Overlap between Responses to a Virus and to the House Dust Mite Allergen in Airway Epithelial Cells. <i>PLoS ONE</i> , 2014, 9, e87768.	2.5	27
119	Histone deacetylase inhibitors up-regulate LL-37 expression independent of toll-like receptor mediated signalling in airway epithelial cells. <i>Journal of Inflammation</i> , 2013, 10, 15.	3.4	23
120	A new therapy (MP29 $\text{\textcircled{O}}2^*$) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity. <i>Clinical and Translational Allergy</i> , 2013, 3, O16.	3.2	0
121	Early growth response protein 1 and dual specificity protein phosphatase 1 are involved in down $\text{\textcircled{O}}$ regulation of allergic responses. <i>Clinical and Translational Allergy</i> , 2013, 3, P26.	3.2	0
122	A new efficacy parameter (complete/near complete symptom relief) in allergic rhinitis management: results with a new therapy MP29 $\text{\textcircled{O}}2^*$. <i>Clinical and Translational Allergy</i> , 2013, 3, P42.	3.2	0
123	Short and long $\text{\textcircled{O}}$ term safety of MP29 $\text{\textcircled{O}}2^*$: a new therapy for the treatment of allergic rhinitis. <i>Clinical and Translational Allergy</i> , 2013, 3, O15.	3.2	3
124	A new therapy (MP29 $\text{\textcircled{O}}2^*$) provides effective relief from all individual nasal and ocular symptoms of seasonal allergic rhinitis. <i>Clinical and Translational Allergy</i> , 2013, 3, P41.	3.2	0
125	A new therapy (MP29 $\text{\textcircled{O}}2^*$) effectively treats patients with seasonal allergic rhinitis who suffer most from the bothersome nasal symptom of congestion. <i>Clinical and Translational Allergy</i> , 2013, 3, P39.	3.2	0
126	A new therapy (MP29 $\text{\textcircled{O}}2^*$) effectively targets the entire seasonal allergic rhinitis symptom complex. <i>Clinical and Translational Allergy</i> , 2013, 3, P45.	3.2	0

#	ARTICLE	IF	CITATIONS
127	Symptoms of chronic rhinosinusitis with and without nasal polyps. <i>Clinical and Translational Allergy</i> , 2013, 3, O2.	3.2	1
128	New Findings in Nonallergic Rhinitis and Local Allergic Rhinitis. <i>Current Otorhinolaryngology Reports</i> , 2013, 1, 106-112.	0.5	1
129	Role of fungi in pathogenesis of chronic rhinosinusitis. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2012, 20, 19-23.	1.8	36
130	No Mucosal Atrophy and Reduced Inflammatory Cells: Active-controlled Trial with Yearlong Fluticasone Furoate Nasal Spray. <i>American Journal of Rhinology and Allergy</i> , 2012, 26, 36-44.	2.0	12
131	Fluticasone furoate nasal spray reduces symptoms of uncomplicated acute rhinosinusitis: a randomised placebo-controlled study. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2012, 21, 267-275.	2.3	21
132	Short-time cold dry air exposure: A useful diagnostic tool for nasal hyperresponsiveness. <i>Laryngoscope</i> , 2012, 122, 2615-2620.	2.0	40
133	EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. <i>Rhinology</i> , 2012, 50, 1-12.	1.3	1,086
134	European Position Paper on Rhinosinusitis and Nasal Polyps 2012. <i>Rhinology Supplement</i> , 2012, 23, 3 p preceding table of contents, 1-298.	6.0	506
135	In response to <i>the Effect of Topical Amphotericin B on Inflammatory Markers in Patients with Chronic Rhinosinusitis: A Multicenter Randomized Controlled Study</i>. <i>Laryngoscope</i> , 2010, 120, 213-214.	2.0	1
136	Preface. <i>Immunology and Allergy Clinics of North America</i> , 2009, 29, xv-xvii.	1.9	0
137	Fungus: A Role in Pathophysiology of Chronic Rhinosinusitis, Disease Modifier, A Treatment Target, or No Role at All?. <i>Immunology and Allergy Clinics of North America</i> , 2009, 29, 677-688.	1.9	44
138	Outpatient therapy for nonallergic rhinitis. <i>Clinical Allergy and Immunology</i> , 2007, 19, 363-73.	0.7	2
139	Role of steroids in the treatment of rhinosinusitis with and without polyposis. <i>Clinical Allergy and Immunology</i> , 2007, 20, 241-50.	0.7	3
140	EP3OS 2007: European position paper on rhinosinusitis and nasal polyps 2007. A summary for otorhinolaryngologists. <i>Rhinology</i> , 2007, 45, 97-101.	1.3	80
141	European position paper on rhinosinusitis and nasal polyps 2007. <i>Rhinology Supplement</i> , 2007, 20, 1-136.	6.0	369